NKTR – Nektar Therapeutics
Nektar TherapeuticsNKTR
$0.5519Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $102,710,800.00
EPSttm : -0.58
Nektar Therapeutics
$0.5519
8.09%$0.0486Float Short %
3.87
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
-0.03
EPS Last/This Y
-0.14
EPS This/Next Y
-0.05
Price
0.56
Target Price
4.36
Analyst Recom
2.11
Performance Q
-42.57
Relative Volume
2.21
Beta
0.68
Ticker: NKTR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | NKTR | 0.864 | 0.08 | 0.00 | 41814 |
| 2025-03-06 | NKTR | 0.86 | 0.08 | 0.02 | 41842 |
| 2025-03-07 | NKTR | 0.8652 | 0.08 | 0.00 | 42230 |
| 2025-03-10 | NKTR | 0.8292 | 0.08 | 0.00 | 42240 |
| 2025-03-11 | NKTR | 0.8184 | 0.08 | 0.00 | 42485 |
| 2025-03-12 | NKTR | 0.8217 | 0.08 | 0.31 | 42601 |
| 2025-03-13 | NKTR | 0.8205 | 0.07 | 0.00 | 42691 |
| 2025-03-14 | NKTR | 0.8968 | 0.07 | 0.06 | 42792 |
| 2025-03-17 | NKTR | 0.9015 | 0.07 | 0.02 | 42971 |
| 2025-03-18 | NKTR | 0.88 | 0.07 | 0.07 | 43250 |
| 2025-03-19 | NKTR | 0.894 | 0.07 | 0.02 | 43350 |
| 2025-03-20 | NKTR | 0.8635 | 0.07 | 0.01 | 43474 |
| 2025-03-21 | NKTR | 0.8579 | 0.07 | 0.02 | 44005 |
| 2025-03-24 | NKTR | 0.8592 | 0.08 | 0.03 | 37319 |
| 2025-03-25 | NKTR | 0.83 | 0.08 | 0.00 | 38432 |
| 2025-03-26 | NKTR | 0.8021 | 0.08 | 0.02 | 38695 |
| 2025-03-27 | NKTR | 0.7522 | 0.08 | 6.08 | 39184 |
| 2025-03-28 | NKTR | 0.74 | 0.06 | 0.03 | 38798 |
| 2025-03-31 | NKTR | 0.68 | 0.05 | 0.06 | 40747 |
| 2025-04-01 | NKTR | 0.6401 | 0.05 | 0.10 | 40875 |
| 2025-04-02 | NKTR | 0.6628 | 0.06 | 0.01 | 41024 |
| 2025-04-03 | NKTR | 0.6043 | 0.05 | 0.02 | 41164 |
| 2025-04-04 | NKTR | 0.5521 | 0.06 | 0.01 | 40813 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | NKTR | 0.86 | 11.4 | - | 0.00 |
| 2025-03-06 | NKTR | 0.86 | 11.4 | - | 0.00 |
| 2025-03-07 | NKTR | 0.86 | 11.4 | - | 0.00 |
| 2025-03-10 | NKTR | 0.82 | 11.4 | - | 0.00 |
| 2025-03-11 | NKTR | 0.81 | 11.4 | - | 0.00 |
| 2025-03-12 | NKTR | 0.82 | 11.4 | - | 0.00 |
| 2025-03-13 | NKTR | 0.82 | 11.4 | - | 0.00 |
| 2025-03-14 | NKTR | 0.90 | 11.4 | - | -0.86 |
| 2025-03-17 | NKTR | 0.91 | 3.6 | - | -0.68 |
| 2025-03-18 | NKTR | 0.88 | 3.6 | - | -0.68 |
| 2025-03-19 | NKTR | 0.90 | 3.6 | - | -0.68 |
| 2025-03-20 | NKTR | 0.87 | 3.6 | - | -0.68 |
| 2025-03-21 | NKTR | 0.87 | 3.6 | - | -0.72 |
| 2025-03-24 | NKTR | 0.86 | 1.3 | - | -0.72 |
| 2025-03-25 | NKTR | 0.84 | 1.3 | - | -0.72 |
| 2025-03-26 | NKTR | 0.80 | 1.3 | - | -0.72 |
| 2025-03-27 | NKTR | 0.75 | 1.3 | - | -0.72 |
| 2025-03-28 | NKTR | 0.74 | 1.3 | - | -0.72 |
| 2025-03-31 | NKTR | 0.68 | 1.3 | - | -0.72 |
| 2025-04-01 | NKTR | 0.64 | 1.3 | - | -0.72 |
| 2025-04-02 | NKTR | 0.66 | 1.3 | - | -0.72 |
| 2025-04-03 | NKTR | 0.60 | 1.3 | - | -0.72 |
| 2025-04-04 | NKTR | 0.56 | 1.3 | - | -0.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | NKTR | -4.42 | -5.95 | 4.21 |
| 2025-03-06 | NKTR | -4.42 | -5.95 | 4.21 |
| 2025-03-07 | NKTR | -4.42 | -5.95 | 4.21 |
| 2025-03-10 | NKTR | -4.42 | -5.95 | 4.21 |
| 2025-03-11 | NKTR | -4.42 | -5.95 | 4.21 |
| 2025-03-12 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-13 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-14 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-17 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-18 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-19 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-20 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-21 | NKTR | -4.42 | -5.95 | 3.73 |
| 2025-03-24 | NKTR | -4.38 | -5.95 | 3.69 |
| 2025-03-25 | NKTR | -4.38 | -5.95 | 3.69 |
| 2025-03-26 | NKTR | -4.38 | -5.95 | 3.87 |
| 2025-03-27 | NKTR | -4.38 | -5.95 | 3.87 |
| 2025-03-28 | NKTR | -4.38 | -5.95 | 3.87 |
| 2025-03-31 | NKTR | -4.38 | -5.93 | 3.87 |
| 2025-04-01 | NKTR | -4.38 | -5.93 | 3.87 |
| 2025-04-02 | NKTR | -4.38 | -5.93 | 3.87 |
| 2025-04-03 | NKTR | -4.38 | -5.93 | 3.87 |
| 2025-04-04 | NKTR | -4.38 | -5.93 | 3.87 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.15
Avg. EPS Est. Current Quarter
-0.18
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
-4.38
Institutional Transactions
-5.93
Beta
0.68
Average Sales Estimate Current Quarter
15
Average Sales Estimate Next Quarter
15
Fair Value
Quality Score
36
Growth Score
31
Sentiment Score
23
Actual DrawDown %
97.9
Max Drawdown 5-Year %
-98.3
Target Price
4.36
P/E
Forward P/E
PEG
P/S
1.04
P/B
1.69
P/Free Cash Flow
EPS
-0.58
Average EPS Est. Cur. Y
-0.72
EPS Next Y. (Est.)
-0.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-120.86
Relative Volume
2.21
Return on Equity vs Sector %
-215.7
Return on Equity vs Industry %
-202.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.14
EBIT Estimation
Nektar TherapeuticsSector: Healthcare
Industry: Biotechnology
Employees: 61
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading